NexDx Adds Biotechnology Leaders Zachary Hornby and Kurt Krummel, Ph.D. to Management Team

San Diego, CA (PRWEB) August 29, 2012

NexDx, Inc. (, a science driven molecular diagnostics company providing next generation products and services for personalized medicine in rheumatoid arthritis and other autoimmune diseases, announced today the additions to its leadership team of Zachary Hornby as vice president, corporate development, and Kurt Krummel, Ph.D. as director, molecular diagnostics and assay development.

Hornby and Dr. Krummel will help lead NexDx as it leverages its epigenomics platform to fundamentally alter the way physicians diagnose and treat autoimmune disease. Studies have demonstrated that rheumatoid arthritis (RA), lupus and several other autoimmune diseases yield distinct epigenetic signatures that can form the basis of new molecular diagnostics, as well as reveal never previously explored targets for therapeutic intervention.

Jonathan Lim, M.D., chairman and CEO of NexDx, Inc., said, The expansion of our leadership team comes at a key point in NexDxs maturation as we recently raised a $ 2.6M Series B that will fuel the rapid progress of our science and business model through key inflection points. Kurt Krummel brings to NexDx a valuable combination of scientific acumen in the areas of advanced molecular techniques, such as next generation sequencing and cell isolation techniques, with project management experience leading teams to develop novel diagnostic tests for a CLIA laboratory. His industry experience will prove critical as NexDx advances its lead initiative of developing a best-in-class molecular diagnostic test for rheumatoid arthritis.

Dr. Lim continued, Zach Hornby provides us with an uncommon breadth of life sciences industry commercial experience spanning business development, marketing, new product planning, and strategy consulting. Zach will play an integral role in helping guide the shaping and execution of NexDxs business strategy, and fostering important partnerships that optimally position NexDx products and services for commercial success.

Dr. Krummel joined NexDx from Celula, Inc., where he served as associate director of biology and managed various teams within an interdisciplinary group of engineers and scientists to develop novel diagnostic tests for a CLIA laboratory. Prior to joining Celula, Dr. Krummel was a postdoctoral researcher at The Salk Institute where his work focused on study of the tumor suppressor gene, p53, and resulted in numerous high profile publications in prestigious peer-reviewed journals such as Proceedings of the National Academy of Sciences, Cancer Cell, Molecular and Cellular Biology, and Genes & Development. Dr. Krummel has a Ph.D. in Molecular Biology from The Mayo Clinic and a Bachelor’s degree in Biology from The University of Wisconsin.

Prior to joining NexDx, Hornby was senior director of business development at Fate Therapeutics where he was responsible for pharmaceutical partnerships and non-dilutive funding. Hornby has also served in various business and commercial roles at Halozyme Therapeutics, Neurocrine Biosciences and TKT (now Shire Human Genetic Therapies), and was a life sciences consultant at L.E.K. Consulting. Hornby holds Bachelors and Masters degrees in biology, with a concentration in neuroscience, from Stanford University and an M.B.A. from Harvard Business School.


NexDx, Inc., located in San Diego, California, is a science driven molecular diagnostics company providing next generation products and services for personalized medicine in rheumatoid arthritis and other autoimmune diseases.

The company, founded in August 2011 by Jonathan E. Lim, M.D. and Gary S. Firestein, M.D. (Professor of Medicine at UC San Diego), is a pioneer in the application of epigenomics and other next generation molecular approaches to the discovery, development, and commercialization of novel biomarkers and tests for diagnostic and therapeutic applications in autoimmune diseases.

The scientific discoveries that led to the founding of NexDx were published in July 2012 in the Annals of the Rheumatic Diseases ( The company recently announced the successful closing of a $ 2.1 million Series B financing led by City Hill Ventures, LLC ( and a $ 500,000 capital term loan from Silicon Valley Bank ( For more information, please visit:

Leave a Reply